Envoy Medical Inc. (COCH)
Official siteHEALTHCARE • MEDICAL DEVICES • NASDAQ
Market Cap: $53.59M
Last updated: Nov 17, 2026 at 4:10 PM ET
Envoy Medical Inc. (COCH) Statistics
Envoy Medical (COCH) has a market cap of $53.59M and an enterprise value of $39.02M. It kept -9026.41% of revenue as net income over the last 12 months. Its share count is up 377.51% from a year earlier.
Total Valuation
Enterprise value is 27.19% below the market cap, as cash exceeds debt.
| Market Cap | $53.59M |
|---|---|
| Enterprise Value | $39.02M |
| Latest price (Nov 17, 2026) | $6.87 |
Key Dates
The next earnings report is expected on Mar 22, 2027, covering the quarter ending Dec 31, 2026.
| Next Earnings Date | Mar 22, 2027 (expected) |
|---|---|
| Last Earnings Date | Nov 5, 2026 |
| Fiscal Year End | December |
Valuation Ratios
The price to sales ratio is 310.3x.
| P/S Ratio | 310.3x |
|---|---|
| Forward P/S | 226.1x |
Price Statistics
The stock is up 2.86% over 52 weeks and trades 1.33% above its 50-day average.
| Beta (1Y) | 1.24 |
|---|---|
| 52-Week Change | +2.86% |
| 1-Month Change | +5.05% |
| 3-Month Change | -7.16% |
| 6-Month Change | -7.16% |
| 5-Year Change | -93.19% |
| Total Return (1Y) | +2.86% |
| Total Return (3Y CAGR) | -8.94% |
| Total Return (5Y CAGR) | -41.20% |
| Return vs SPY (1Y) | -21.88% |
| Max Drawdown (1Y) | -54.00% |
| Max Drawdown (3Y) | -96.08% |
| Sharpe Ratio (1Y) | -0.12 |
| Correlation with SPY (1Y) | 0.19 |
| 50-Day Average | $6.78 |
| 200-Day Average | $6.88 |
| 52-Week Range | $3.63 to $9.54 |
| RSI (14 Days) | 52.6 |
| Average Volume (20 Days) | 80.23K |
The 5-year change compares month-end closes, adjusted for splits, through Oct 2026.
Financial Position
Current assets cover 1.21x current liabilities, and total debt is 0.00x shareholder equity.
| Current Ratio | 1.21x |
|---|---|
| Quick Ratio | 1.10x |
| Debt / Equity | 0.00x |
Returns and Efficiency
| Return on Assets (ROA) | -108.84% |
|---|---|
| Return on Capital Employed (ROCE) | -426.58% |
| ROIC (5Y Average) | 339.66% |
| Asset Turnover | 0.02x |
| Inventory Turnover | 0.68x |
| Receivables Turnover | 3.45x |
| Cash Conversion Cycle | 14 days |
Scores
COCH has an Altman Z-Score of -25.51, in the distress zone below 1.81, and a Piotroski F-Score of 2 of 9, in the weak band of 0 to 2.
Altman Z-ScoreDistress below 1.81Safe above 2.99
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Altman Z-Score | -25.51 |
|---|---|
| Altman Z Zone | Distress |
| Piotroski F-Score | 2 of 9 |
| Piotroski Strength | Weak |
Income Statement
Revenue of $231.00K over the last 12 months is up 11.06% from the 12 months before.
| Revenue | $231.00K |
|---|---|
| Revenue Growth (YoY) | +11.06% |
| Gross Profit | -$815.00K |
| Operating Income | -$23.45M |
| Pretax Income | -$20.85M |
| Net Income | -$20.85M |
| EBITDA | -$19.63M |
| EBIT | -$20.85M |
| Reported EPS (TTM) | -$3.32 |
Trailing 12 months through Sep 30, 2026.
Balance Sheet
| Cash and Equivalents | $14.57M |
|---|---|
| Total Debt | $0 |
| Net Cash | $14.57M |
| Net Cash Per Share | $1.40 |
| Working Capital | $2.99M |
| Shareholder Equity | -$1.53M |
| Total Assets | $19.16M |
| Total Liabilities | $20.30M |
Balance sheet as of Sep 30, 2026.
Cash Flow
After $205.00K of capital spending, operating cash flow left -$22.44M of free cash flow.
| Operating Cash Flow | -$22.23M |
|---|---|
| Capital Expenditures | $205.00K |
| Free Cash Flow | -$22.44M |
| FCF Per Share | -$2.90 |
| Depreciation and Amortization | $1.22M |
Trailing 12 months through Sep 30, 2026.
Margins
The operating margin is -10151.52%.
| Gross Margin | -352.81% |
|---|---|
| Operating Margin | -10151.52% |
| Pretax Margin | -9026.41% |
| Net Margin | -9026.41% |
| EBITDA Margin | -8496.97% |
| EBIT Margin | -9026.41% |
| FCF Margin | -9712.99% |
Dividends and Yields
COCH does not pay a dividend. Its free cash flow yield is -31.30%.
| FCF Yield | -31.30% |
|---|---|
| Buyback Yield | -43.70% |
Stock Splits
The last split was a 1-for-10 reverse split on Oct 26, 2026.
| Last Split Date | Oct 26, 2026 |
|---|---|
| Split Type | Reverse split |
| Split Ratio | 1:10 |
Peer Position
Against 12 similar companies, COCH has the highest P/S.
P/S RatioPeer median 1.7x
Revenue Growth (Trailing 4 Quarters, YoY)Peer median +9.04%
| P/S Ratio | 310.3x vs 1.7x median |
|---|---|
| Revenue Growth (Trailing 4 Quarters, YoY) | +11.06% vs +9.04% median |
Analyst Forecast
Consensus estimates put revenue growth at 6.50% a year over the next 2 fiscal years.
| Revenue Growth Forecast (2Y CAGR) | +6.50% |
|---|
Price Target
Analyst price targets are part of paid GNG plans. See plans
Frequently Asked Questions About COCH
What is COCH's market cap?
Envoy Medical has a market cap of $53.59M. Its enterprise value, which adds debt and subtracts cash, is $39.02M.
How many shares of COCH are outstanding?
Envoy Medical has 10.43M shares outstanding. The count is up 377.51% from a year earlier.
Does COCH pay a dividend?
No. Envoy Medical does not pay a dividend.
How much debt does COCH have?
Envoy Medical has $0 of total debt and $14.57M of cash and equivalents, a net cash position of $14.57M.
COCH pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Competitors